[Form 4] LAVA Therapeutics NV Insider Trading Activity

Rhea-AI Filing Summary

LAVA Therapeutics N.V. (LVTX) reported an insider equity transaction by its Chief Financial Officer. On 11/13/2025, the CFO disposed of 65,000 common shares and had 124,700 share options cancelled. Both actions were carried out under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation.

Each common share was exchanged for $1.04 in cash plus one non-transferable contingent value right (CVR). Each in-the-money option was cancelled in return for cash, based on the excess of $1.04 over the option’s exercise price, and one CVR per underlying share, net of applicable taxes and deductions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Powell Fred M

(Last) (First) (Middle)

C/O LAVA THERAPEUTICS N.V.

YALELAAN 62

(Street)

UTRECHT P7 3584 CM

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/13/2025		D		65,000	D	(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Options (Right to Buy)	$0.93	11/13/2025		D			124,700	(2)	02/12/2035	Common Shares	124,700	$0	0	D

Explanation of Responses:

1. Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.

2. This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

	/s/ Amy Garabedian, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LAVA Therapeutics (LVTX) report in this Form 4?

The Chief Financial Officer of LAVA Therapeutics N.V. (LVTX) reported disposing of 65,000 common shares and cancelling 124,700 share options on 11/13/2025 under a Purchase Agreement with XOMA Royalty Corporation.

What consideration did LVTX shareholders receive in the reported transaction?

Each common share was exchanged for $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share, as described in the Purchase Agreement with XOMA Royalty Corporation.

How were LAVA Therapeutics (LVTX) share options treated in this Form 4 event?

Each in-the-money option was cancelled and the holder received cash equal to the excess of $1.04 over the option’s exercise price, multiplied by the number of underlying shares, plus one CVR per underlying share, net of applicable taxes and deductions.

Who is the reporting person in this LVTX Form 4 and what is their role?

The reporting person is an officer of LAVA Therapeutics N.V., serving as the company’s Chief Financial Officer, as indicated in the relationship section of the filing.

Is the LAVA Therapeutics (LVTX) Form 4 a joint filing with other insiders?

No. The document indicates that the Form 4 is filed by one reporting person, not by more than one reporting person.

What is the transaction date reported for the LVTX CFO’s Form 4 filing?

The date of the earliest transaction reported for the LAVA Therapeutics N.V. CFO is 11/13/2025, which applies to both the common share disposition and the option cancellation.